Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of 64Cu Pembrolizumab PET Imaging for In Vivo Expression of PD1

NCT04605614 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT04605614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04605614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of 64Cu Pembrolizumab PET Imaging for In Vivo Expression of PD1
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Withdrawn
Start date
April 15, 2022
Completion date
May 16, 2022
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic and lymphoid cell neoplasm, malignant solid neoplasm